Long-term Outcomes of Ablation, Liver Resection, and Liver Transplant as First-line Treatment for Solitary HCC of 3 cm or Less

University Health Network, Toronto

Status

Completed

Conditions

Hepatocellular Carcinoma

Treatments

Procedure: Liver transplantation

Procedure: Liver resection

Procedure: Radiofrequency ablation

Study type

Observational

Funder types

Other

Identifiers

NCT05193253

16-5285.6

Details and patient eligibility

About

Curative-intent therapies for hepatocellular carcinoma (HCC) include radiofrequency ablation (RFA), liver resection (LR), and liver transplantation (LT). Controversy exists in treatment selection for early-stage tumors. We sought to evaluate the oncologic outcomes of patients who received either RFA, LR, or LT as first-line treatment for solitary HCC ≤ 3cm in an intention-to-treat analysis.

Enrollment

119 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult (≥18 years) patients
Solitary HCC ≤ 3cm
Receipt of either radiofrequency ablation, liver resection, or listing for a liver transplant
Treatment received between Feb-2000 and Nov-2018

Exclusion criteria

Pathology other than hepatocellular carcinoma (HCC)
Receipt of prior treatment (i.e., not treatment naive)
Not eligible for all of the three treatments (ablation, liver resection, or liver transplant listing)
Platelet count <100,000 before treatment
Alpha-1 fetoprotein (AFP) level > 1000 before treatment
Age > 70 years
Child-Pugh score C
Esophageal varices grade greater than 2
Model for End-stage Liver Disease (MELD) score before treatment exceeding 15
Presence of ascites pretreatment
Presence of encephalopathy pretreatment
Spleen size greater than 12 cm